How Bitterman was paid
$1.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Robert J. BittermanPresident and Chief Executive Officer | $419,054 | — | $580,000 | $158,400 | $1,978 | $1,159,432 |
| Lisa C. CarsonChief Financial Officer | $188,081 | $25,000 | $109,040 | $50,198 | $697 | $373,015 |
| Robert M. InfarinatoFormer Vice President and Chief Financial Officer | $126,113 | $40,000 | — | — | $60,575 | $226,688 |
What changed and why
- $1.2M$1,159,432: CEO total compensation in 2025, compared with $387,019 in 2024.
- $580K$580,000: CEO restricted stock unit grant-date fair value in 2025.
- 50%50%: CEO target annual bonus opportunity after the February 2026 employment agreement amendment.
- 250,000: RSUs granted to the CEO in September 2025, vesting fully after one year.
- $60,000$60,000: Severance payment included in former CFO Robert Infarinato’s 2025 other compensation.
- 2025 bonuses were based on achievement of formal corporate objectives.
Other Phio Pharmaceuticals proxy statements
- 2025 proxy statement
Robert J. Bitterman paid $387,019 (-12% on the year).
Filed Jul 30, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.